
# ASTHMA

NCT05851443

## Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Povorcitinib in Participants With Inadequately Controlled Moderate-to-Severe Asthma




### 1 PRIMARY ENDPOINT

- Absolute change from baseline in pre-BD FEV1 at week 24

### 2 SELECT SECONDARY ENDPOINTS

- Number of asthma exacerbations up to 24 weeks
- Absolute and percent change from baseline in pre-BD FEV1 and in pre-BD FVC at each visit up to 14 months
- Absolute change and percent change from baseline in post-BD FEV1 at week 24

For more information, please visit: https://clinicaltrials.gov/study/NCT05851443

### SELECT INCLUSION CRITERIA

- Physician-diagnosed moderate-to-severe asthma treated with medium- to high-dose ICS-LABA for ≥12 months prior to screening
- Pre-BD FEV1 <80% predicted at visit 2[a]
- Documented historical post-BD reversibility of FEV1 ≥12% and ≥200 mL in FEV1 or airway hyper-responsiveness within 24 months prior to screening or post-BD reversibility of FEV1 ≥12% and ≥200 mL in FEV1 at visit 2
- ≥2 documented asthma exacerbations[b] within 12 months but not within the past 4 weeks prior to screening
- ACQ-6 score ≥1.5 at screening

### SELECT EXCLUSION CRITERIA

- Use of asthma controllers other than ICS-LABA
- Have undergone bronchial thermoplasty
- Current smokers, participants with a smoking history of ≥10 pack-years, and participants using vaping products
- Current conditions or history of: important pulmonary disease (other than asthma), thrombocytopenia, coagulopathy, platelet dysfunction, cardiovascular diseases, disease or organ transplantation requiring immunosuppresion, malignancies, chronic or recurrent infectious disease
- Receipt of any biologic drugs used for asthma <12 weeks or 5 half-lives (if known), whichever is longer, prior to screening

[a]Still within the screening period. [b]Defined as a worsening of asthma requiring treatment with systemic corticosteroids, hospitalization, or emergency department visit.

The efficacy and safety of the investigational compound and/or uses discussed have not been established. There is no guarantee that this compound will become commercially available for the use(s) under investigation.

For more information, visit **IncyteClinicalTrials.com** or contact us at **1-855-4MEDINFO** (855-463-3463) or by email at **clintrials@incyte.com**

ACQ-6, Asthma Control Questionnaire - 6 Items; BD, bronchodilator; EOS, end of study; EOT, end of treatment; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; ICS-LABA, inhaled corticosteroid and a long-acting β2-adrenergic receptor agonist; JAK, Janus kinase; QD, once daily.

ClinicalTrials.gov. Accessed Jul 2026. https://clinicaltrials.gov/study/NCT05851443; Data on file. Incyte Corporation.

This information is current as of July 8, 2026.

©2026, Incyte. CON-POV-US-0003 08/26